William D. Tap

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari et al. · Nature Genetics · 2019 · 4.2K citations · Full text

Cancer Immunosurveillance, Tumor Heterogeneity, Medicine +9

Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Margaret von Mehren, R. Lor Randall, Robert S. Benjamin et al. · Journal of the National Comprehensive Cancer Network · 2018 · 720 citations · Full text

Surgical Oncology, Cancer Management, Pathology +16

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

Sandra P. D’Angelo, Michelle R. Mahoney, Brian Andrew Van Tine et al. · The Lancet Oncology · 2018 · 716 citations · Full text

Oncology, Ipilimumab Treatment, Clinical Trials +8

PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors

William Lee, Sewit Teckie, Thomas Wiesner et al. · Nature Genetics · 2014 · 615 citations · Full text

Malignant Disease, Suz12 Loss, Pathology +6

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

Bastien Nguyen, Christopher J. Fong, Anisha Luthra et al. · Cell · 2022 · 608 citations · Full text

Urology, Tumor Heterogeneity, Medicine +11